
DRNA
Healthcare · Biotechnology · $2.98B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2021
EPS trend, 90 days to now · -31.7% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2021 | After the close | -0.50 | -0.22 | +56.0% |
| Aug 9, 2021 | After the close | 0.28 | -0.53 | -291.0% |
| May 6, 2021 | After the close | -0.37 | -0.39 | -5.5% |
| Feb 25, 2021 | After the close | -0.05 | -0.49 | -920.8% |
| Nov 5, 2020 | After the close | -0.24 | -0.29 | -19.4% |
| Aug 6, 2020 | After the close | 0.10 | -0.43 | -514.7% |
| May 7, 2020 | After the close | 0.27 | -0.31 | -216.3% |
| Feb 27, 2020 | After the close | -0.32 | -0.58 | -80.5% |
| Nov 7, 2019 | After the close | -0.28 | -0.45 | -58.0% |
| Aug 8, 2019 | After the close | -0.31 | -0.35 | -12.9% |
| May 9, 2019 | After the close | -0.22 | -0.38 | -73.8% |
| Mar 11, 2019 | After the close | -0.27 | -0.29 | -5.9% |
| Nov 5, 2018 | After the close | -0.27 |
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and…
| -0.35 |
| -30.9% |
| Aug 8, 2018 | After the close | -0.44 | -0.68 | -53.8% |
| May 14, 2018 | After the close | -0.38 | -0.30 | +21.5% |
| Mar 8, 2018 | After the close | -0.60 | -0.90 | -49.2% |